Kenneth B. Newman
Corporate Officer/Principal at IONIS PHARMACEUTICALS, INC.
Profile
Kenneth B.
Newman is currently the Senior Vice President-Clinical Development at Ionis Pharmaceuticals, Inc. He previously worked as the Executive Director at Forest Laboratories, Inc., Chief Development Officer at Mesoblast, Inc., Chief Medical Officer & EVP-Clinical Development at Acton Pharmaceuticals, Inc., and Vice President at Boehringer Ingelheim Corp.
He also served as the Chief Medical Officer at Verona Pharma Plc from 2015 to 2018.
Newman received his undergraduate degree from Duke University, his MBA from Carl H.
Lindner College of Business, and his doctorate from The University of Texas Health Science Center at Houston.
Kenneth B. Newman active positions
| Companies | Position | Start |
|---|---|---|
| IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Former positions of Kenneth B. Newman
| Companies | Position | End |
|---|---|---|
| VERONA PHARMA PLC | Chief Tech/Sci/R&D Officer | 29/04/2018 |
Mesoblast, Inc.
 Mesoblast, Inc. Pharmaceuticals: MajorHealth Technology Mesoblast, Inc. manufactures and distributes biopharmaceutical products. It develops cellular medicines for under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. The company was founded by Michael Schuster and Silviu Itescu in 2004 and is headquartered in New York, NY. | Corporate Officer/Principal | 30/11/2014 |
Acton Pharmaceuticals, Inc.
 Acton Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Acton Pharmaceuticals, Inc. developed and commercialized pharmaceutical products. The company was founded by John W. Simon and Daniel L. Kreisler in 2008 and is headquartered in Marlborough, MA. | Chief Tech/Sci/R&D Officer | 31/10/2013 |
Boehringer Ingelheim Corp.
 Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Corporate Officer/Principal | 31/12/2008 |
| FOREST LABORATORIES, INC. | Director/Board Member | - |
Training of Kenneth B. Newman
| Duke University | Undergraduate Degree |
| Carl H. Lindner College of Business | Masters Business Admin |
| The University of Texas Health Science Center at Houston | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| VERONA PHARMA PLC | Health Technology |
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Acton Pharmaceuticals, Inc.
Acton Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Acton Pharmaceuticals, Inc. developed and commercialized pharmaceutical products. The company was founded by John W. Simon and Daniel L. Kreisler in 2008 and is headquartered in Marlborough, MA. | Health Technology |
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Health Technology |
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY. | Health Technology |
Mesoblast, Inc.
Mesoblast, Inc. Pharmaceuticals: MajorHealth Technology Mesoblast, Inc. manufactures and distributes biopharmaceutical products. It develops cellular medicines for under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. The company was founded by Michael Schuster and Silviu Itescu in 2004 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Kenneth B. Newman
